Ultra-sensitive bioanalysis of the therapeutic peptide exenatide for accurate pharmacokinetic analyses at effective plasma concentrations utilizing UPLC-MS/MS

[1]  T. Bækdal,et al.  Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes , 2019, Clinical Pharmacokinetics.

[2]  W. Haefeli,et al.  An ultrasensitive UPLC-MS/MS assay for the quantification of the therapeutic peptide liraglutide in plasma to assess the oral and nasal bioavailability in beagle dogs. , 2019, Bioanalysis.

[3]  V. Flynn,et al.  Persistent injection site nodules from exenatide: Successful treatment with intralesional triamcinolone , 2018, JAAD Case Reports.

[4]  Irl B Hirsch,et al.  AACE/ACE Consensus Statement CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM – 2018 EXECUTIVE SUMMARY , 2018 .

[5]  S. Chaudhry,et al.  Exenatide-Induced Panniculitis: Utility of the Acid-Fast Stain to Identify Injected Microspheres. , 2017, The American Journal of dermatopathology.

[6]  T. Vilsbøll,et al.  Exenatide: pharmacokinetics, clinical use, and future directions , 2017, Expert opinion on pharmacotherapy.

[7]  A. Brinker,et al.  Injection-Site Nodules Associated With the Use of Exenatide Extended-Release Reported to the U.S. Food and Drug Administration Adverse Event Reporting System , 2015, Diabetes Spectrum.

[8]  Á. Santos-Briz,et al.  Exenatide-Induced Eosinophil-Rich Granulomatous Panniculitis: A Novel Case Showing Injected Microspheres. , 2015, The American Journal of dermatopathology.

[9]  Ying Guo,et al.  Exenatide-induced eosinophilic sclerosing lipogranuloma at the injection site. , 2014, The American Journal of dermatopathology.

[10]  M. Stone,et al.  Eosinophil‐rich granulomatous panniculitis caused by exenatide injection , 2014, Journal of cutaneous pathology.

[11]  K. Mace,et al.  Pharmacokinetics, safety, and tolerability of single‐ and multiple‐dose exenatide once weekly in Chinese patients with type 2 diabetes mellitus (对中国2型糖尿病患者单次和多次给予艾塞那肽周制剂的药代动力学、安全性和耐受性研究) , 2013, Journal of diabetes.

[12]  Fabio Garofolo,et al.  Large-molecule quantification: sensitivity and selectivity head-to-head comparison of triple quadrupole with Q-TOF. , 2013, Bioanalysis.

[13]  D. Mager,et al.  Interspecies Modeling and Prediction of Human Exenatide Pharmacokinetics , 2013, Pharmaceutical Research.

[14]  Jinfeng Zhang,et al.  Ultra-high-performance liquid chromatography for the determination of exenatide in monkey plasma by tandem quadrupole mass spectrometry , 2012, Journal of pharmaceutical analysis.

[15]  Chester L. Bowen,et al.  Application of DBS for quantitative assessment of the peptide Exendin-4; comparison of plasma and DBS method by UHPLC-MS/MS. , 2010, Bioanalysis.

[16]  M. Fineman,et al.  Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study. , 2009, Clinical therapeutics.

[17]  Y. Isaka,et al.  Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Mellitus , 2008, Journal of clinical pharmacology.

[18]  Dennis D. Kim,et al.  Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. , 2005, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[19]  A. Young,et al.  Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes , 2004, Regulatory Peptides.

[20]  Dennis D. Kim,et al.  Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. , 2003, Diabetes care.

[21]  B. Matuszewski,et al.  Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. , 2003, Analytical chemistry.

[22]  G. Frost,et al.  Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. , 2001, American journal of physiology. Endocrinology and metabolism.

[23]  J. Raufman,et al.  Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. , 1992, The Journal of biological chemistry.

[24]  M. Fineman,et al.  Pharmacokinetics and Pharmacodynamics of Exenatide Extended-Release After Single and Multiple Dosing , 2011, Clinical Pharmacokinetics.